J&J Spots Potential Of Fate’s Stem Cells, Signs Cancer Deal Worth Up To $3bn

Another Next-Generation Approach to CAR-Ts

Investment from Janssen helps to validate the platform developed by the San Diego-based company.

Johnson_and_Johnson

While the world and the biopharma sector are focused on solving the COVID-19 pandemic, companies haven’t forgotten the promise of next-generation cancer treatments.

Johnson & Johnson has just signed a major new deal with San Diego-based Fate Therapeutics aimed at using induced...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip